A growing U.S. shortage of Adderall, a prescription drug taken to treat attention deficit hyperactivity disorder, has spread to two more makers of the drug.
Lannett Co. and Par Pharmaceuticals are the most recent companies experiencing with limited supplies of generic extended-release Adderall, according to the University of Utah Pharmacy Services website, which tracks drug shortages nationwide
Lannett spokesperson Robert Jaffe confirmed to USA TODAY Wednesday the company is seeing spikes in demand for its 15-milligram extended-release pills. Quotas on how much Adderall can be made also affects supply, Jaffe said.
US move to curb pill overdose deaths:US appointed ‘drug czar’ plans to counter Mexican drug cartels, reduce overdose deaths
Fake Adderall pills laced with meth:Feds seize ‘staggering’ amount of fake Adderall pills laced with meth in Rhode Island
Adderall has often been in short supply over recent years. The most recent issue started with a labor shortage in August at Teva Pharmaceutical Industries Ltd., the nation’s leading seller of instant-release Adderall, Bloomberg reported.
Demand for the drug is at an all-time high, Symphony Health told the outlet.
Nine companies supply branded and generic Adderall in the nation, Erin Fox, senior pharmacy director at the University of Utah’s drug-information service told USA TODAY. Other firms facing supply challenges for the drug include Amneal Pharmaceuticals Inc., Rhodes Pharmaceuticals LP and Novartis AG’s Sandoz unit.
Fox said those three companies did not provide a specific reason for their shortages to the university.
What’s everyone talking about?:Sign up for our trending newsletter to get the latest news of the day
The Food and Drug Administration previously reported there was a nationwide shortage of the drug in September 2019 that lasted until May 2022 due to demand increase in the drug.
But as of Wednesday, the FDA was not reporting a current reporting a shortage of Adderall.